Company: TAK
Filing Date: 2025-07-30
Form Type: 6-K
Source: 0001395064-25-000120
Chunk: 15

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-07-30
Form: 6-K
Chunk 15
---
 |     | -14.4 | % |     |     | -10.3 | %                         |
| Core net profit for the period attributable to owners of the Company             |     |            |     | 276.8 |     |           |     | 237.0 |     |          |     | -39.8 |     | -14.4 | % |     |     | -10.3 | %                         |

During the periods presented, these items fluctuated as follows:

#### Core Net Finance Expenses
Core Net Finance Expenses were JPY 31.3 billion (JPY +1.2 billion and +4.1% AER , +4.4% CER ).

Core Share of Profit (Loss) of Investments Accounted for Using the Equity Method

For the three-month period ended June 30, 2025, Core Share of Loss of Investments Accounted for Using the Equity Method was JPY 0.1 billion (JPY -0.5 billion). For the three-month period ended June 30, 2024, Core Share of Profit of Investments Accounted for Using the Equity Method was JPY 0.4 billion.

#### Core Profit Before Tax
Core Profit Before Tax was JPY 290.4 billion (JPY -62.2 billion and -17.6% AER , -13.4% CER ).

#### Core Income Tax Expenses
Core Income Tax Expenses were JPY 53.3 billion (JPY -22.4 billion and -29.6% AER , -24.8% CER ). The decrease was primarily due to the effect of a higher valuation allowance on deferred tax assets recognized during the three-month period ended June 30, 2024 and lower pretax earnings partially offset by an increase in tax expenses due to lower level of tax credits recognized during the three-month period ended June 30, 2025.

#### Core

#### EPS
Core EPS was JPY 151 (JPY -25 and -14.1% AER, -10.0% CER).

<div align='center'>8</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Three-month

Period Ended June 30, 2025 (Consolidated)

### (2) Consolidated Financial Position
(i) Assets, Liabilities and Equity

|                   |     | As of | March 31, 2025